Intercept to Present at Upcoming Investor Conference

NEW YORK, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in following investor conference:

• BMO Prescriptions for Success Healthcare Conference on December 14, 2016 at 1:00 p.m. Eastern Time

Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

For more information about Intercept Pharmaceuticals, please contact:

Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]

Media inquiries: [email protected]

Investor inquiries: [email protected]

Source: Intercept Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rice's OpenStax awarded $90M to lead first-of-its-kind NSF research hub for transformational learning and education research
• Motlow State Community College Expands Accessibility With the Addition of YuJa Panorama Digital Accessibility Platform to Its Ed-Tech Tools
• BayCare's St. Joseph's Hospital Opens Season's Café with Amazon's Just Walk Out Technology